These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 37105270)

  • 21. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
    Sun C; Su Z; Zeng YP
    Inflamm Res; 2023 Sep; 72(9):1861-1871. PubMed ID: 37707560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
    Front Immunol; 2020; 11():620098. PubMed ID: 33658996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib.
    Nogueira M; Torres T
    Dermatol Pract Concept; 2021 Oct; 11(4):e2021145. PubMed ID: 35024237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging therapies for atopic dermatitis: JAK inhibitors.
    Cotter DG; Schairer D; Eichenfield L
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abrocitinib in atopic dermatitis: review of the current literature and clinical trials.
    Napolitano M; Fornaro L; Potestio L; Fabbrocini G; Patruno C
    Drugs Today (Barc); 2022 Aug; 58(8):373-387. PubMed ID: 35983924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis.
    Narla S; Silverberg JI
    Dermatitis; 2024; 35(S1):S24-S38. PubMed ID: 37527229
    [No Abstract]   [Full Text] [Related]  

  • 30. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
    Narla S; Silverberg JI
    Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
    Alves C; Penedones A; Mendes D; Batel Marques F
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan.
    Hagino T; Yoshida M; Hamada R; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2023 Dec; 34(1):2276043. PubMed ID: 38073228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.
    Montilla AM; Gómez-García F; Gómez-Arias PJ; Gay-Mimbrera J; Hernández-Parada J; Isla-Tejera B; Ruano J
    Dermatol Ther (Heidelb); 2019 Dec; 9(4):655-683. PubMed ID: 31606872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
    Yoon S; Kim K; Shin K; Kim HS; Kim B; Kim MB; Ko HC; Kim YH
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):52-61. PubMed ID: 37597261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
    He Q; Xie X; Chen Q; Li W; Song Z; Wang X; Ma X; Zeng J; Guo J
    Front Immunol; 2024; 15():1342810. PubMed ID: 38464512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
    Cinats A; Heck E; Robertson L
    Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
    Muddebihal A; Khurana A; Sardana K
    Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Janus kinase inhibitors in atopic dermatitis - an update.
    Dhar S; Datta S; De A
    Indian J Dermatol Venereol Leprol; 2023 Oct; ():1-8. PubMed ID: 38031681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety.
    Elmariah SB; Smith JS; Merola JF
    Am J Clin Dermatol; 2022 Jul; 23(4):427-431. PubMed ID: 35679017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.